of February 10, 2023 No. 29
About establishment of the Republican form of medicines for 2023
Based on part one of article 38-1 of the Law of the Republic of Belarus of June 18, 1993 No. 2435-XII "About health care", the paragraph of the fifteenth subitem 8.8-5 of Item 8 and subitem 9.1 of Item 9 of the Regulations on the Ministry of Health of the Republic of Belarus approved by the resolution of Council of Ministers of the Republic of Belarus of October 28, 2011 No. 1446, the Ministry of Health of the Republic of Belarus DECIDES:
1. Establish the Republican form of medicines for 2023 according to appendix.
2. This resolution becomes effective after its official publication.
Minister
D.L.Pinevich
Appendix
to the Resolution of the Ministry of Health of the Republic of Belarus of February 10, 2023 No. 29
№ |
Pharmacological subgroup anatomo - therapeutic and chemical classification system of medicines |
International non-proprietary name of medicine |
Dosage forms, dosages |
Reference information about the medicine price, conventional units |
The dosage forms, dosages made and (or) which are packed up in the Republic of Belarus |
Note |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
1 |
A Digestive tract and metabolism | |||||
1.1 |
Means A02 for treatment of the conditions connected with acidity violation: | |||||
1.1.1 |
A02A Antatsidny means |
The connections containing hydroxide of aluminum and magnesium |
Suspension for internal application |
– |
Suspension for internal application |
– |
Tablets (chewable tablets) |
– |
Tablets (chewable tablets) |
||||
Aluminum phosphate |
Suspension |
– |
Suspension |
– | ||
1.1.2 |
A02B the Antiulcer means and means applied in case of gastroezofagealny reflux disease |
Lansoprazol |
Capsules (capsules kishechnorastvorimy) 15 mg |
– |
– |
– |
Capsules (capsules kishechnorastvorimy) 30 mg |
– |
Capsules of 30 mg |
– | |||
Omeprazol |
The powder lyophilized for preparation of solution for intravenous administration (lyophilisate for preparation of solution for intravenous administration) 40 mg |
0,983 |
The powder lyophilized for preparation of solution for intravenous administration (lyophilisate for preparation of solution for intravenous administration) 40 mg |
– | ||
Capsules of 10 mg |
– |
– |
||||
Capsules (capsules kishechnorastvorimy) 20 mg |
– |
Capsules (capsules kishechnorastvorimy) 20 mg |
||||
Pantoprazol |
The lyophilized powder (powder) for preparation of solution for intravenous administration of 40 mg |
0,976 |
The lyophilized powder for preparation of solution for intravenous administration of 40 mg |
– | ||
The tablets covered with kishechnorastvorimy cover (tablets kishechnorastvorimy), 40 mg |
– |
The tablets covered with kishechnorastvorimy cover, 40 mg |
||||
Ranitidine |
Solution for injections (solution for intravenous and intramuscular administration) 25 mg/ml 2 ml |
– |
Solution for intravenous and intramuscular administration of 25 mg/ml 2 ml |
– | ||
The tablets covered with cover, 75 mg |
– |
– | ||||
The tablets covered with cover, 150 mg |
– |
The tablets covered with cover, 150 mg | ||||
The tablets covered with cover, 300 mg |
– |
– |
||||
Famotidin |
The lyophilized powder for injections (for preparation of solution for intravenous administration) 20 mg |
1,467 |
– |
– | ||
The tablets covered with cover, 20 mg |
– |
The tablets covered with cover, 20 mg |
||||
The tablets covered with cover, 40 mg |
– |
The tablets covered with cover, 40 mg |
||||
1.2 |
Means A03 for treatment of functional violations of digestive tract: | |||||
1.2.1 |
The Means A03A applied in case of dysfunction of intestines |
Synthetic spazmolitichesky means, amides with tertiary amino group (platifillin) |
Solution for hypodermic introduction of 2 mg/ml 1 ml |
– |
– |
– |
Papaverine |
Solution for injections of 20 mg/ml 2 ml |
– |
Solution for injections of 20 mg/ml 2 ml |
– | ||
Suppositories rectal 20 mg |
– |
– |
||||
Drotaverin |
Solution for intravenous and intramuscular administration (for injections) 20 mg/ml 2 ml |
– |
Solution for intravenous and intramuscular administration (for injections) 20 mg/ml 2 ml |
– | ||
Tablets of 40 mg |
– |
Tablets of 40 mg |
||||
Tablets of 80 mg |
– |
– |
||||
Silicones (in children's practice) |
Drops for intake of 40 mg/ml 30 ml, 50 ml |
– |
Drops for intake of 40 mg/ml 30 ml, 50 ml |
– | ||
Drops for intake of 66,66 of mg/ml of 30 ml |
– |
– |
||||
Drops for internal application of 300 mg/ml 30 ml |
– |
– |
||||
1.2.2 |
Means A03B on the basis of belladonna and its derivatives |
Atropine |
Solution for injections of 1 mg/ml 1 ml |
– |
Solution for injections of 1 mg/ml 1 ml |
– |
1.2.3 |
Spazmolitiki's A03D in combination with analgetics |
Pitofenon in combination with analgetics |
Solution for intramuscular introduction (for injections) |
– |
Solution for intramuscular introduction |
– |
1.2.4 |
Pro-kinetics A03F |
Domperidon |
Tablets of 10 mg |
– |
Tablets of 10 mg |
– |
The tablets covered with cover, 10 mg |
– |
The tablets covered with cover, 10 mg |
||||
Metoklopramid |
Solution for intravenous and intramuscular administration (for injections) 5 mg/ml 2 ml |
– |
Solution for intravenous and intramuscular administration of 5 mg/ml 2 ml |
– | ||
Tablets of 10 mg |
– |
Tablets of 10 mg |
||||
1.3 |
A04 Protivorvotny means and means for elimination of nausea: | |||||
A04A Protivorvotny means and means for elimination of nausea |
Aprepitant |
Capsules of 125 mg, capsules of 80 mg |
18,1 |
– |
It is appointed based on the conclusion of medical consultation (except for crews of emergency medical service, intensive care units and intensive therapy) | |
Granisetron (in children's practice) |
Concentrate for preparation of solution for infusions of 1 mg/ml 3 ml |
– |
– |
– | ||
Solution for injections of 1 mg/ml 3 ml |
18,262 |
– |
||||
The tablets covered with cover, 1 mg |
– |
– |
||||
Ondansetron |
Solution for intravenous and intramuscular administration (for injections) 2 mg/ml 2 ml |
– |
Solution for intravenous and intramuscular administration of 2 mg/ml 2 ml |
– | ||
Solution for intravenous and intramuscular administration (for injections) 2 mg/ml 4 ml |
– |
Solution for intravenous and intramuscular administration of 2 mg/ml 4 ml |
||||
The tablets covered with cover, 4 mg |
– |
– |
||||
The tablets covered with cover, 8 mg |
0,217 |
The tablets covered with cover, 8 mg |
||||
Tropisetron |
Solution for intravenous administration (for injections) 1 mg/ml 5 ml |
– |
Solution for intravenous administration (for injections) 1 mg/ml 5 ml |
– | ||
Capsules of 5 mg |
– |
Capsules of 5 mg |
||||
1.4 |
Means A05 for treatment of diseases of liver and biliary tract: | |||||
1.4.1 |
Means A05A for treatment of diseases of biliary tract |
Ursodeoksikholevy (ursodezoksikholevy) acid |
Capsules of 250 mg |
– |
Capsules of 250 mg |
– |
Capsules of 300 mg |
– |
Capsules of 300 mg |
||||
Suspension for intake of 250 mg / 5 ml, |
– |
Suspension for intake of 250 mg / 5 ml, |
– | |||
Other medicines in case of diseases of biliary tract (artichoke extract) |
Solution for intake of 120 ml |
– |
Solution for intake of 120 ml |
– | ||
Capsules of 100 mg |
– |
Capsules of 100 mg |
||||
The tablets covered with cover, 200 mg |
– |
The tablets covered with cover, 200 mg |
||||
1.4.2 |
Means A05B for treatment of diseases of liver, lipotropny means |
Ornitina aspartate |
Concentrate for preparation of solution for infusions of 500 mg/ml 10 ml |
4,847 |
Concentrate for preparation of solution for infusions of 500 mg/ml |
– |
Solution for infusions (for injections) 100 mg/ml 10 ml |
– |
Solution for infusions of 100 mg/ml 10 ml |
||||
Powder for preparation of solution for internal application of 3 g |
– |
Powder for preparation of solution for internal application of 3 g |
||||
Granules for preparation of solution for intake of 5 g |
0,734 |
– |
||||
Silimarin |
The tablets covered with cover, 35 mg |
– |
The tablets covered with cover, 35 mg |
– | ||
Phospholipids/glycyrrhizic acid |
Lyophilisate for preparation of solution for intravenous administration of 2,5 of |
– |
– |
– | ||
Capsules |
– |
Capsules |
||||
Essentsialny phospholipids |
Solution for intravenous administration of 50 mg/ml 5 ml |
– |
Solution for intravenous administration of 50 mg/ml 5 ml |
– | ||
Capsules |
– |
Capsules |
||||
1.5 |
A06 Depletive: | |||||
A06A Depletive |
Liquid paraffin (vaseline oil) |
Oil of 30 ml |
– |
Oil of 30 ml |
– | |
Bisakodil |
Tablets are the kishechnorastvorimy, covered cover (the tablet covered with kishechnorastvorimy cover), 5 mg |
– |
Tablets are kishechnorastvorimy, covered with cover, 5 mg |
– | ||
Castor oil |
Oil for intake of 30 g |
– |
Oil for intake of 30 g |
– | ||
Pikosulfat of sodium |
Drops for intake (for internal application) mg/ml 7,5 |
– |
Drops for internal application of 7,5 of mg/ml |
– | ||
Magnesium sulfate |
Powder for preparation of solution for internal application of 10 g, 20 g |
– |
Powder for preparation of solution for internal application of 10 g, 20 g |
– | ||
Laktuloza |
Syrup of 500-670 mg/ml |
– |
Syrup of 667-670 mg/ml 150 ml-500 of ml |
– | ||
Macrogoal |
Powder for preparation of solution for intake (for internal application) 10 g |
– |
Powder for preparation of solution for intake (for internal application) 10 g |
– | ||
Macrogoal in combinations |
Powder for preparation of solution for intake (for internal application) |
– |
Powder for preparation of solution for intake (for internal application) |
– | ||
1.6 |
A07 Antidiarrheal means, anti-inflammatory, anti-infectious means for intestines: | |||||
1.6.1 |
A07A the Antimicrobic means operating on intestines |
Nystatin |
The tablets covered with cover, 500 000 ED |
– |
The tablets covered with cover, 500 000 ED |
– |
Suppositories rectal 250 000 ED |
– |
– |
||||
Suppositories rectal 500 000 ED |
– |
Suppositories rectal 500 000 ED |
||||
Nifuroksazid |
Suspension for internal application of 44 mg/ml 90 ml |
– |
Suspension for internal application of 44 mg/ml 90 ml |
– | ||
The tablets covered with cover, 100 mg |
– |
The tablets covered with cover, 100 mg |
||||
Capsules of 100 mg |
– |
Capsules of 100 mg |
– | |||
Capsules of 200 mg |
– |
Capsules of 200 mg |
||||
1.6.2 |
A07B Intestinal adsorbents |
Diosmektit (in children's practice) |
Powder for preparation of suspension for internal application (for intake) 3 000 mg |
– |
Powder for preparation of suspension for internal application (for intake) 3 000 mg |
– |
The coal activated |
Tablets of 250 mg |
– |
Tablets of 250 mg |
– | ||
1.6.3 |
A07C Electrolytes with carbohydrates |
Salt complexes for oral regidratation |
Powder for preparation of solution for internal application (for intake) |
– |
Powder for preparation of solution for internal application |
– |
1.6.4 |
The Means A07D reducing motor function of digestive tract |
Loperamide |
Capsules of 2 mg |
– |
Capsules of 2 mg |
– |
1.6.5 |
A07E the Resolvents operating on intestines |
Mesalazin |
The tablets covered with kishechnorastvorimy cover, 250 mg |
– |
– |
– |
The tablets covered with kishechnorastvorimy cover, 400 mg |
– |
The tablets covered with kishechnorastvorimy cover, 400 mg | ||||
The tablets covered with kishechnorastvorimy cover, 500 mg |
– |
– |
||||
Suppositories rectal 250 mg |
– |
Suppositories rectal 250 mg |
||||
Suppositories rectal 500 mg |
– |
Suppositories rectal 500 mg |
||||
Granules of the prolonged action of 1 g in sachet |
– |
– |
||||
Granules of the prolonged action of 2 g in sachet |
– |
– |
||||
Suspension of rectal 4 g / 60 ml in bottles of 60 ml |
7,310 |
– |
||||
Sulfasalazin |
The tablets covered with cover (the tablet covered with kishechnorastvorimy cover), 500 mg |
– |
The tablets covered with cover, 500 mg |
– | ||
1.6.6 |
A07F the Antidiarrheal means of biological origin regulating balance of intestinal microflora (probiotics) |
Bakteriyny medicines for treatment of dysfunctions of intestines |
The lyophilized powder for preparation of suspension for intake (the powder lyophilized for preparation of suspension for intake) of 5 doses |
– |
The lyophilized powder for preparation of suspension for intake (the powder lyophilized for preparation of suspension for intake) of 5 doses |
– |
1.7 |
The Means A09 normalizing digestion, including fermental means: | |||||
The Means A09A promoting digestion including enzymes |
The multienzymes containing lipase, amylase, protease (for treatment of cystous fibrosis, when growing cancer of stomach into pancreas head) |
Capsules are kishechnorastvorimy, 10 000 ED |
0,187 |
Capsules kishechnorastvorimy 10 000 ED |
– | |
Capsules are kishechnorastvorimy, 25 000 ED |
0,37 |
– |
||||
1.8 |
Means A10 for treatment of diabetes: | |||||
1.8.1 |
A10A Insulin and their analogs |
Insulin of the person (short action) |
Solution for injections of 100 ME/ml in bottles of 10 ml |
7,16 |
Solution for injections of 100 ME/ml in bottles of 10 ml |
– |
Solution for injections of 100 ME/ml in cartridges of 3 ml |
– |
Solution for injections of 100 ME/ml in cartridges of 3 ml |
||||
Insulin of the person (long action) |
Suspension for injections of 100 ME/ml in bottles of 10 ml |
7,16 |
Suspension for injections of 100 ME/ml in bottles of 10 ml |
– | ||
Suspension for hypodermic introduction (suspension for injections) 100 ME/ml in cartridges of 3 ml |
– |
Suspension for hypodermic introduction of 100 ME/ml in cartridges of 3 ml |
||||
Insulin aspart |
Suspension for hypodermic introduction of 100 PIECES/ml in cartridges of 3 ml |
– |
– |
It is appointed based on the conclusion of medical consultation (except for crews of emergency medical service, intensive care units and intensive therapy) | ||
Solution for hypodermic 100 PIECES/ml in cartridges of 3 ml |
8,894 |
– | ||||
Insulin glargin (long action) |
Solution for injections of 100 PIECES/ml in cartridges of 3 ml |
13,453 |
Solution for injections of 100 PIECES/ml in cartridges of 3 ml |
It is appointed based on the conclusion of medical consultation (except for crews of emergency medical service, intensive care units and intensive therapy) | ||
Solution for hypodermic introduction of 300 PIECES/ml in the syringe handles Solostar of 1,5 of ml |
23,326 |
– |
||||
Insulin detemir (long action) |
Solution for hypodermic introduction of 100 PIECES/ml in the syringe handles of 3 ml |
12,526 |
– |
It is appointed based on the conclusion of medical consultation (except for crews of emergency medical service, intensive care units and intensive therapy) | ||
Insulin glulizin (short action) |
Solution for hypodermic introduction of 100 PIECES/ml in the syringe handles Solostar of 3 ml |
– |
– |
It is appointed based on the conclusion of medical consultation (except for crews of emergency medical service, intensive care units and intensive therapy) | ||
Solution for hypodermic introduction of 100 PIECES/ml in cartridges of 3 ml |
10,292 |
– | ||||
Insulin of the person (aktrapid) (short action) |
Solution for injections for hypodermic and intravenous administration of 100 ME/ml in bottles of 10 ml of NM |
9,807 |
– |
– | ||
Solution for injections of 100 ME/ml in cartridges of 3 ml of NM Penfill |
3,222 |
Solution for injections of 100 ME/ml in cartridges of 3 ml | ||||
Insulin of the person (protafan) (average duration of action) |
Suspension for hypodermic introduction of 100 ME/ml in bottles of 10 ml of NM |
9,278 |
Suspension for hypodermic introduction of 100 ME/ml in bottles of 10 ml |
– | ||
Suspension for hypodermic introduction of 100 ME/ml in cartridges of 3 ml of NM Penfill |
3,222 |
Suspension for hypodermic introduction of 100 ME/ml in cartridges of 3 ml |
||||
Insulin of the person (gensulin) |
Solution for injections of 100 ME/ml in bottles of 10 ml P |
9,817 |
– |
– | ||
Suspension for injections of 100 ME/ml in bottles of 10 ml of N |
9,817 |
– |
||||
Solution for injections of 100 ME/ml in cartridges of 3 ml P |
3,725 |
– |
||||
Suspension for injections of 100 ME/ml in cartridges of 3 ml of N |
3,725 |
– |
||||
Insulin of the person (insuman) |
Solution for injections of 100 ME/ml in the syringe handles Solostar of 3 ml |
– |
– |
– | ||
Solution for injections of 100 ME/ml in bottles of 5 ml Slow motion of GT |
– |
– | ||||
Suspension for hypodermic introduction of 100 ME/ml in the syringe handles Solostar of 3 ml |
– |
– |
||||
Suspension for hypodermic introduction of 100 ME/ml in bottles of 5 ml Bazal GT |
– |
– |
||||
Insulin of the person (humulin) |
Solution for injections of 100 ME/ml in bottles of 10 ml Regulyar |
8,107 |
– |
– | ||
Suspension for hypodermic introduction of 100 ME/ml in bottles of 10 ml of NPH |
8,107 |
– |
||||
Solution for injections of 100 ME/ml in cartridges of 3 ml Regulyar |
5,923 |
– |
||||
Suspension for hypodermic introduction of 100 ME/ml in cartridges of 3 ml of NPH |
5,904 |
– |
||||
1.8.2 |
A10B Oral gipoglikemiziruyushchy means |
Glibenclamide |
Mg tablets 3,5 |
– |
– |
– |
Tablets of 5 mg |
– |
Tablets of 5 mg |
– | |||
Glikvidon |
Tablets of 30 mg |
0,117 |
Tablets of 30 mg |
– | ||
Gliclazide |
Tablets of 30 mg with the modified release |
– |
Tablets of 30 mg with the modified release |
– | ||
Tablets of 60 mg with the modified release |
– |
Tablets of 60 mg with the modified release |
||||
Tablets of 80 mg |
– |
Tablets of 80 mg |
||||
Glimepirid |
Tablets of 2 mg |
– |
– |
– | ||
Tablets of 4 mg |
– |
– |
||||
Tablets of 6 mg |
– |
– |
||||
Liraglutid |
Solution for hypodermic introduction of 6 mg/ml 3 ml |
– |
– |
– | ||
Metformin |
Tablets of 500 mg |
– |
Tablets of 500 mg |
– | ||
The tablets covered with cover, 500 mg |
– |
The tablets covered with cover, 500 mg |
||||
Tablets with the modified release of 500 mg |
– |
Tablets with the modified release of 500 mg |
||||
Tablets with the modified release of 750 mg |
– |
Tablets with the modified release of 750 mg |
||||
The tablets covered with cover, 850 mg |
– |
The tablets covered with cover, 850 mg |
||||
The tablets covered with cover, 1 000 mg |
– |
The tablets covered with cover, 1 000 mg |
||||
Tablets with the modified release of 1 000 mg |
– |
Tablets with the modified release of 1 000 mg |
||||
Metformin/glibenclamide |
The tablets covered with cover, 500 mg / 2,5 of mg |
– |
The tablets covered with cover, 500 mg / 2,5 of mg |
– | ||
Tablets (the tablet covered with cover) of 500 mg / 5 mg |
– |
Tablets (the tablet covered with cover) of 500 mg / 5 mg |
||||
Vildagliptin |
Tablets of 50 mg |
0,768 |
– |
It is appointed based on the conclusion of medical consultation (except for crews of emergency medical service, intensive care units and intensive therapy) | ||
Dapagliflozin |
The tablets covered with cover, 10 mg |
– |
– |
– | ||
Empagliflozin |
The tablets covered with cover, 10 mg |
– |
– |
– | ||
The tablets covered with cover, 25 mg |
– |
– |
– | |||
1.9 |
A11 Vitamins | |||||
1.9.1 |
A11B Polyvitamins |
b-karotin/Kislota ascorbic / |
Powder for preparation of solution for internal application in packets |
– |
Powder for preparation of solution for internal application in packets |
– |
1.9.2 |
A11C Vitamins A and D and their combinations |
Kaltsitriol |
Mkg 0,25 capsules |
– |
– |
– |
Retinolum (vitamin A) |
Solution 34,4 of mg/ml of 10 ml, oil for internal application |
– |
– |
– | ||
Capsules of 33 000 ME |
– |
Capsules of 33 000 ME | ||||
Capsules of 5 000 ME |
– |
Capsules of 5 000 ME | ||||
Holekaltsiferol |
Drops (solution) for intake of 15 000 ME/ml of 10 ml, 15 ml, 20 ml |
– |
Drops for intake of 15 000 ME/ml of 10 ml, 15 ml, 20 ml |
– | ||
Solution for intake oil (drop) 0,5 of mg/ml (20 000 ME/ml) of 10 ml |
– |
Solution for intake oil 0,5 of mg/ml |
||||
Capsules of 2 000 ME |
– |
Capsules of 2 000 ME |
||||
Capsules of 5 000 ME |
– |
Capsules of 5 000 ME |
||||
Capsules of 50 000 ME |
– |
Capsules of 50 000 ME |
||||
Ergokaltsiferol (vitamin D 2) |
Solution 1,25 of mg/ml of 10 ml, oil for internal application |
– |
– |
– | ||
1.9.3 |
A11D B1 Vitamin and its combinations with B6 and B12 vitamins |
Vitamin B6/B1/vitamin |
Solution for intramuscular introduction of 2 ml |
– |
Solution for intramuscular introduction of 2 ml |
– |
Vitamin B6/B1/vitamin |
Solution for intramuscular introduction of 2 ml |
– |
Solution for intramuscular introduction of 2 ml |
– | ||
Thiamine |
Solution for intramuscular introduction of 50 mg/ml 1 ml |
– |
Solution for intramuscular introduction of 50 mg/ml 1 ml |
– | ||
1.9.4 |
A11G Ascorbic acid (vitamin C), including combinations with other means |
Ascorbic acid |
Solution for intravenous and intramuscular administration of 50 mg/ml 2 ml |
– |
Solution for intravenous and intramuscular administration of 50 mg/ml 2 ml |
– |
1.9.5 |
A11H Other vitamins (excepting combinations) |
Pyridoxine |
Solution for injections of 50 mg/ml 1 ml |
– |
Solution for injections of 50 mg/ml 1 ml |
– |
Powder (substance for powder preparation) (in children's practice) |
– |
– |
||||
Tocopherol |
Drops for internal application oil (solution oil) 50 mg/ml 20 ml |
– |
– |
– | ||
Drops for internal application oil (solution oil) 100 mg/ml 20 ml |
– |
– | ||||
Drops for internal application oil (solution oil) 300 mg/ml 20 ml |
– |
– |
||||
1.10 |
A12 Mineral additives: | |||||
1.10.1 |
Means A12A on the basis of calcium |
Calcium gluconate |
Solution for injections of 100 mg/ml 5 ml, 10 ml |
– |
– |
– |
Tablets of 500 mg |
– |
Tablets of 500 mg |
||||
Calcium / Holekaltsiferol |
Mg 66,7 ME/166,7 capsules |
– |
Mg 66,7 ME/166,7 capsules |
– | ||
Mg 133,4 ME/166,7 capsules |
– |
Mg 133,4 ME/166,7 capsules |
||||
Tablets chewing 500 mg / 0,005 of mg (200 ME) |
– |
Tablets chewing 500 mg / 0,005 of mg (200 ME) |
||||
1.10.2 |
A12C Other mineral additives |
The complex medicines containing ions of potassium and magnesium |
Tablets of 175 mg / 175 mg |
– |
– |
– |
The tablets covered with cover, 140 mg / 158 in mg |
– |
The tablets covered with cover, 140 mg / 158 in mg |
||||
Zinc sulfate |
The tablets covered with cover, 124 mg |
– |
– |
– | ||
1.11 |
A14 Anabolic medicines for system application: | |||||
A14B Other anabolic substances |
Methyluracil |
Suppositories rectal 500 mg |
– |
– |
– | |
1.12 |
A16 Other means for treatment of diseases of digestive tract and metabolic disorders: | |||||
1.12.1 |
A16AA of Amino acid and their derivatives |
Ademetionin |
The lyophilized powder for preparation of solution for injections of 500 mg |
0,012 |
– |
– |
The tablets covered with kishechnorastvorimy cover, 500 mg |
– |
The tablets covered with kishechnorastvorimy cover, 500 mg |
– | |||
Gepavilag (valin/leytsin/ |
Granules for preparation of solution for intake |
– |
Granules for preparation of solution for intake |
– | ||
Tavamin (valin/izoleytsin/ |
Capsules |
– |
Capsules |
– | ||
Left carnitine (for patients on hemodialysis) |
Solution for intravenous administration (for injections) 200 mg/ml 5 ml |
1,081 |
Solution for intravenous administration of 200 mg/ml 5 ml |
– | ||
1.12.2 |
A16AX Other means for treatment of diseases of digestive tract and metabolic disorders |
Tioktovy acid |
Solution for intravenous administration of 25 mg/ml 24 ml |
1,45 |
Solution for intravenous administration of 25 mg/ml 24 ml |
– |
Concentrate for preparation of solution for infusions of 30 mg/ml 10 ml, 20 ml |
1,45 |
Concentrate for preparation of solution for infusions of 30 mg/ml 10 ml, 20 ml | ||||
Solution for infusions of 30 mg/ml 10 ml, 20 ml |
– |
– | ||||
Solution for infusions of 12 mg/ml 50 ml |
– |
Solution for infusions of 12 mg/ml 50 ml | ||||
The tablets covered with cover, 300 mg |
– |
– | ||||
The tablets covered with cover, 600 mg |
– |
The tablets covered with cover, 600 mg |
||||
2 |
B Blood and haematogenic bodies | |||||
2.1 |
B01 Antitrombotichesky means: | |||||
2.1.1 |
B01AA Antagonists of vitamin K |
Fenindion |
Tablets of 30 mg |
– |
– |
– |
Varfarin |
Mg tablets 2,5 |
– |
Mg tablets 2,5 |
– | ||
Tablets of 5 mg |
– |
– |
||||
2.1.2 |
B01AB Direct anticoagulants on the basis of heparin and its derivatives |
Heparin |
Solution for intravenous and hypodermic administration (for injections) 5 000 ME/ml of 5 ml |
– |
Solution for intravenous and hypodermic administration of 5 000 PIECES/ml 5 ml |
– |
Anti-thrombin III |
The lyophilized powder for preparation of solution for intravenous infusions of 50 ME/ml 500 ME |
– |
– |
It is appointed based on the conclusion of medical consultation (except for crews of emergency medical service, intensive care units and intensive therapy) | ||
The lyophilized powder for preparation of solution for intravenous infusions of 50 ME/ml of 1 000 ME |
611,51 |
– | ||||
Dalteparin |
Solution for injections of 2 500 ME of anti-Xa/0,2 of ml |
2,773 |
– |
It is appointed based on the conclusion of medical consultation (except for crews of emergency medical service, intensive care units and intensive therapy) | ||
Solution for injections of 5 000 ME of anti-Xa/0,2 of ml |
4,121 |
– | ||||
Solution for injections of 10 000 ME of anti-Xa/1 of ml |
6,413 |
– | ||||
Enoksaparin |
Solution for injections 2 000 Anti-ha ml ME/0,2 |
2,373 |
Solution for injections 2 000 Anti-ha ml ME/0,2 |
It is appointed based on the conclusion of medical consultation (except for crews of emergency medical service, intensive care units and intensive therapy) | ||
Solution for injections 4 000 Anti-ha ml ME/0,4 |
2,668 |
Solution for injections 4 000 Anti-ha ml ME/0,4 | ||||
Solution for injections 6 000 Anti-ha ml ME/0,6 |
3,599 |
Solution for injections 6 000 Anti-ha ml ME/0,6 | ||||
Solution for injections 8 000 Anti-ha ml ME/0,8 |
4,544 |
Solution for injections 8 000 Anti-ha ml ME/0,8 | ||||
Nadroparin |
Solution for hypodermic introduction of 2 850 ME of anti-Xa/0,3 of ml |
4,128 |
– |
It is appointed based on the conclusion of medical consultation (except for crews of emergency medical service, intensive care units and intensive therapy) | ||
Solution for hypodermic introduction of 3 800 ME of anti-Xa/0,4 of ml |
6,640 |
– | ||||
Solution for hypodermic introduction of 5 700 ME of anti-Xa/0,6 of ml |
8,556 |
– | ||||
Solution for hypodermic introduction of 7 600 ME of anti-Xa/0,8 of ml |
11,271 |
– | ||||
Solution for hypodermic introduction of 11 400 ME of anti-Xa/0,6 of ml |
– |
– | ||||
Bemiparin |
Solution for injections of 2 500 ME of anti-Xa/0,2 of ml |
2,328 |
– |
It is appointed based on the conclusion of medical consultation (except for crews of emergency medical service, intensive care units and intensive therapy) | ||
Solution for injections of 3 500 ME of anti-Xa/0,2 of ml |
2,908 |
– | ||||
2.1.3 |
B01AC Inhibitors of aggregation of platelets, excepting heparin |
Klopidogrel |
The tablets covered with cover, 75 mg |
– |
The tablets covered with cover, 75 mg |
– |
Capsules of 75 mg |
– |
Capsules of 75 mg | ||||
Dipiridamol |
For injections (for infusions) 5 mg/ml 2 ml |
0,158 |
– |
– | ||
Tablets (the tablet covered with cover) of 25 mg |
– |
– |
||||
Acetilsalicylic acid |
The tablets covered with kishechnorastvorimy cover, 50 mg |
– |
– |
– | ||
The tablets covered with kishechnorastvorimy cover (tablets kishechnorastvorimy, covered with cover) 75 mg |
– |
The tablets covered with kishechnorastvorimy cover (tablets kishechnorastvorimy, covered with cover) 75 mg | ||||
The tablets covered with cover, 75 mg |
– |
The tablets covered with cover, 75 mg | ||||
The tablets covered with kishechnorastvorimy cover, 100 mg |
– |
– | ||||
The tablets covered with kishechnorastvorimy cover (tablets kishechnorastvorimy, covered with cover) 150 mg |
– |
The tablets covered with kishechnorastvorimy cover (tablets kishechnorastvorimy, covered with cover) 150 mg | ||||
The tablets covered with cover, 150 mg |
– |
The tablets covered with cover, 150 mg | ||||
Ticagrelor |
The tablets covered with cover, 60 mg |
– |
The tablets covered with cover, 60 mg |
It is appointed based on the conclusion of medical consultation (except for crews of emergency medical service, intensive care units and intensive therapy) | ||
The tablets covered with cover, 90 mg |
– |
The tablets covered with cover, 90 mg | ||||
2.1.4 |
B01AD Fibrinolytic means on the basis of enzymes |
Streptokinase |
The powder lyophilized for preparation of solution for injections of 750 000 ME |
– |
The powder lyophilized for preparation of solution for injections of 750 000 ME |
– |
The powder lyophilized for preparation of solution for injections of 1 500 000 ME |
– |
The powder lyophilized for preparation of solution for injections of 1 500 000 ME |
||||
Alteplaza |
Lyophilisate for preparation of solution for infusions of 50 mg |
585,766 |
– |
It is appointed based on the conclusion of medical consultation (except for crews of emergency medical service, intensive care units and intensive therapy) | ||
Tenekteplaza |
Lyophilisate (the powder lyophilized) for preparation of solution for intravenous administration of 10 000 PIECES 50 mg in bottles complete with the solvent |
902,763 |
The powder lyophilized for preparation of solution for intravenous administration of 50 mg in bottles complete with the solvent |
It is appointed based on the conclusion of medical consultation (except for crews of emergency medical service, intensive care units and intensive therapy) | ||
The powder lyophilized for preparation of solution for intravenous administration of 40 mg in bottles complete with the solvent |
586,888 |
The powder lyophilized for preparation of solution for intravenous administration of 40 mg in bottles complete with the solvent | ||||
2.1.5 |
B01AE Direct inhibitors of thrombin |
Dabigatrana eteksilat |
Capsules of 75 mg |
– |
– |
It is appointed based on the conclusion of medical consultation (except for crews of emergency medical service, intensive care units and intensive therapy) |
Capsules of 110 mg |
– |
– | ||||
Capsules of 150 mg |
– |
– |
Disclaimer! This text was translated by AI translator and is not a valid juridical document. No warranty. No claim. More info
Database include more 50000 documents. You can find needed documents using search system. For effective work you can mix any on documents parameters: country, documents type, date range, teams or tags.
More about search system
If you cannot find the required document, or you do not know where to begin, go to Help section.
In this section, we’ve tried to describe in detail the features and capabilities of the system, as well as the most effective techniques for working with the database.
You also may open the section Frequently asked questions. This section provides answers to questions set by users.